Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 27.07.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. WO2020142740 - TREATMENT OF SJOGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS

Publication Number WO/2020/142740
Publication Date 09.07.2020
International Application No. PCT/US2020/012258
International Filing Date 03.01.2020
IPC
A61K 47/68 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
CPC
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K 2317/524
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
52Constant or Fc region; Isotype
524CH2 domain
C07K 2317/71
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
71Decreased effector function due to an Fc-modification
C07K 2319/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applicants
  • RESOLVE THERAPEUTICS, LLC [US]/[US]
Inventors
  • POSADA, James, Arthur
  • BURGE, Daniel, M.D.
Agents
  • MANDRAGOURAS, Amy, E.
  • BRULEY, Kenneth, C.
  • MANDRAGOURAS, Amy, E.
  • BAUER, John
  • BREZEZINSKI, Ashley, T.
Priority Data
62/788,73004.01.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF SJOGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS
(FR) TRAITEMENT DE LA MALADIE DE SJÖGREN À L'AIDE DE PROTÉINES DE FUSION DE TYPE NUCLÉASES
Abstract
(EN)
The present disclosure provides methods for treating Sjogren's disease by administering nuclease fusion proteins. The methods of the disclosure are useful to treat symptoms associated with Sjogren's disease, including fatigue.
(FR)
La présente invention concerne des méthodes de traitement de la maladie de Sjögren par administration de protéines de fusion de type nucléases. Les procédés de l'invention sont utiles pour traiter des symptômes associés à la maladie de Sjögren, y compris la fatigue.
Also published as
IL284519
Latest bibliographic data on file with the International Bureau